Polaryx Therapeutics, Inc. SEC filings PLYX

Polaryx Therapeutics, Inc. has 35 filings in SEC EDGAR's recent list, going back to Aug 5, 2025. Its latest annual report, Form ARS, was filed on Jul 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 14, 2026 (shareholder vote results). The company's fiscal year ends on December 31.

Polaryx Therapeutics, Inc. SEC filings
Form Description Filed Period
4 Insider transaction May 28, 2026 May 27, 2026
4 Insider transaction Feb 20, 2026 Feb 18, 2026
SCHEDULE 13D Ownership over 5% (active) Feb 5, 2026 —
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026
3 Initial insider ownership Jan 29, 2026 Jan 29, 2026

Showing 10 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
PLYX (Nasdaq)
Fiscal year ends
December 31
Incorporated in
WY
Headquarters
Paramus, NJ
SEC filer status
, Emerging growth company
SEC CIK
2075320

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.